The company generated revenue of $24.29 million for the fourth quarter of 2025, which was below the analyst estimate of $24.48 million. Revenue for the quarter increased significantly from $0.03 million in the same period last year.
The company reported a loss of $0.34 per share for the fourth quarter, which was wider than the consensus estimate of a $0.27 loss per share. This loss per share represented an increase from the $0.09 loss per share reported in the fourth quarter of the previous year.
AUCATZYL net product revenue for the fourth quarter of 2025 was $23.3 million, contributing to a full-year total of $74.3 million. The company continues to project AUCATZYL net product revenue for 2026 to be between $120 million and $135 million.
Dr. Christian Itin, Chief Executive Officer of Autolus, said, “Autolus had a strong first year of launch of AUCATZYL in the US building a market leading position in adult patients with relapsed or refractory B-ALL and demonstrating strong commercial execution, including reliable, high-quality product delivery with consistent turn-around time.”
